



#15/D  
K/PAV15

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:  
Stewart D. Lyman and M. Patricia Beckmann

Attorney Docket No.: 2813-L

Serial No.: 08/994,468

Technology Center: 1633

Filed: December 19, 1997

Examiner: J. Kerr

CPA Filed: May 26, 2000

For: MEDIUM CONTAINING FLT3 LIGAND FOR  
CULTURING HEMATOPOIETIC CELLS

**AMENDMENT AND RESPONSE**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated August 14, 2000 (Paper No. 14), and pursuant to Rule 111 of the Rules of Practice, Applicants offer the following remarks. Pursuant to Rule 121 of the Rules of Practice, attached hereto are marked-up copies of pages 38 and 43 showing the changes made to the specification, and a marked-up version of claim 2 can be found on page 7. Reconsideration of the above-captioned application is respectfully requested.

**Amendments**

*In the specification:*

At page 1, line 15, after "December 7, 1993, now abandoned" please cancel the remaining text of this paragraph (which extends to line 19), and replace it with a period.

At page 38, lines 6-9, please replace the existing table with the following table:

	<u>Control</u>	<u>flt3-L</u>	<u>IL-7</u>	<u>flt3-L + IL-7</u>
[ <sup>3</sup> H]-thymidine incorporation (CPM)	100	1000	100	4200